# Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

> **NCT01048333** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 109 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Formoterol
- **DRUG:** Salmeterol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01048333
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2012-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048333, "Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01048333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*